1 / 27

DIAGNOSIS & PENATALAKSANAAN LEUKEMIA KRONIK

DIAGNOSIS & PENATALAKSANAAN LEUKEMIA KRONIK. IRZA WAHID SUBBAGIAN HEMATOLOGI DAN ONKOLOGI MEDIK BAGIAN I. PENY DALAM FK UNAND - RS DR M DJAMIL PADANG.

deidra
Télécharger la présentation

DIAGNOSIS & PENATALAKSANAAN LEUKEMIA KRONIK

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DIAGNOSIS & PENATALAKSANAANLEUKEMIA KRONIK IRZA WAHID SUBBAGIAN HEMATOLOGI DAN ONKOLOGI MEDIK BAGIAN I. PENY DALAM FK UNAND - RS DR M DJAMIL PADANG

  2. LEUKEMIADefinisi : AbnormalitasProliferasi / diferensiasiselindukdarahSerial MieloidSerial LimfoidLeukemia mieloblastikakutLeukemia limfoblastikakut( Tu. Dewasamuda ) ( Tu. Anak-anak ) Leukemia mielositikkronik Leukemia limfositikkronik ( Dewasamuda + orangtua ) ( Semuaumur )

  3. Hematopoeitik :Sum-sum tulang --------------------------------> Darah tepiI. Myeloid progenitor cell A.Erythro-MKprogenitor cellEritropoesis  eritrosit  Anemia / PolisitemiaMegakariopoesis  trombosit  Trombositosis / Trombositopenia B.Gran-mono progenitor cellGranulopoesis  leukosit  Leukopenia / LeukositosisMonositopoesis  monosit  Monositopenia / MonositosisII. Lymphoid progenitor cellLimfopoesis limfosit  Limfositopenia / Limfositosis  sel plasma Extramedular ------------------------------------> Hati / Limpa

  4. INSIDEN : SEKITAR 3 %2004 Estimated US Cancer Deaths • 25% Lung & bronchus • 15% Breast • 10% Colon & rectum • 6% Ovary • 6% Pancreas • 4% Leukemia • 3% Non-Hodgkin lymphoma • 3% Uterine corpus • 2% Multiple myeloma • 2% Brain/ONS • 24% All other sites Lung & bronchus 32% Prostate 10% Colon & rectum 10% Pancreas 5% Leukemia 5% Non-Hodgkin 4%lymphoma Esophagus 4% Liver & intrahepatic 3%bile duct Urinary bladder 3% Kidney 3% All other sites 21% Men290,890 Women272,810 ONS=Other nervous system. Source: American Cancer Society, 2004.

  5. DISTRIBUSI LEUKEMIA DI RSKD (1993-2000) Agus Kosasih et al.

  6. PATHOGENESIS OF HEMATOLOGIC MALIGNANCY

  7. Diagnosis Klinis Sitomorfologi Sitokimia Immunophenotype Sitogenetik Molecular

  8. LEUKEMIA MIELOSITIK KRONIK

  9. Myeloproliferative disorders • Typical CML  variant : chronic eosinophilic leukemia chronic basophilic leukemia chronic neutrophilic leukemia • Idiophatic Myelofibrosis • Polycythemia vera • Essential thrombocytemia • Chronic myelomonocytic leukemia • Atypical CML

  10. Figure 3. Classification of myeloproliferative neoplasms on the basic of molecular pathogenetic characteristics. (Campbell PJ et al, 2006)

  11. DEFINITION • CLONAL STEM CELL DISORDERS • INCREASED PROLIFERATION OF MYELOID ELEMENTS AT ALL STAGES DIFFERENTIATION

  12. Translokasi kromosom 9 dan 22 : Philadelphia chromosome (CML) Fusi gen BCR - ABL Leukemogenesis

  13. PerjalananPenyakit1. Fasekronik CLINICAL & SYMPTOMS % Fatigue 83 Weight loss 61 Abdominal fullness & anorexia 38 Easy bruising or bleeding 35 abdominal pain 33 fever 11 splenomegali 95 sternal tenderness 78 lymphadenophaty 64 hepatomegaly 48 purpura 27 retinal hemmorhage 21

  14. PERIPHERAL BLOOD & BONE MARROW • anemia ringan, normositik normokrom • leukositosis 20 – 60.000 /mm3 • trombosit 500 – 600000 /mm3 • morfologi darah tepi : tu mielosit & netrofil segmen •  SST : hiperseluler, myeloblast  netrofil segmen

  15. 2. Accelerated phase • Panas /B.B turun tanpa sebab • Splenomegali yg sulit dikendalikan • Progressieve pancytopenie • Progressieve leukocytosis yg cepat • Kenaikan blast (>10%) in blood or bone marrow • Lebih dari 20% blast + promyelocyte in blood or bone marrow • Basofilia (>20%) • Additionale chromosomale abnomalities (e.g. iso 17, +8, 2e t (9;22)) • Resintent with standard cytostatica

  16. 3. Blastic crisis phase • >20% blast di darah perifer atau >30% sumsum tulang atau • >30% blast + promyelocyte di darah perifer atau • >50% blast + promyelocyte di sumsum tulang atau di extramedullaire lokalisatie

  17. Penatalaksanaan1. Supportif2. Kemoterapi Hydroxi urea ( Hydrea 500 mg)  Fase kronik / akselerasi* Leukosit 20000 – 150000  50 mg/kgbb/hr 3 dosis s/d leukosit < 20.000* Leukosit > 150.000  leukoferesis  20 mg/kgb s/d leu 5000 – 15000 Fase Krisis blast Hidroxyurea 20 mg/kgbb+ 6 MP1,5–2,5 mg/kgbb + Pred 60 /m2  Median survival : 4 – 5 yrs

  18. Alternatif  Busulfan  Median survival : 4 – 5 yrs  Interferon alfa  Median survival : 5 – 8 yrs  Imatinib mesylate  Dasatinib • Definitif  Transplantasi sum-sum tulang  Median survival : 7 – 10 yrs

  19. Leukemia LimfositikKronik

  20. LYMPHOMA GRADATION ( NCCN 2010 ) • Indolent (slow growing) B-cell lymphomas • Follicular lymphoma • Chronic lymphocytic leukemia • MALT • Splenic marginal zone lymphoma • Nodal marginal zone • Aggressive (fast growing) B-cell lymphomas • Diffuse large B-cell lymphoma • Mantle cell lymphoma • Highly aggressive B-cell lymphomas • Burkitt lymphoma • Lymphoblastic lymphoma / AIDS-related B-cell

  21. T and NK-Cell Neoplasms Precursor T-cell neoplasm Precursor T-lymphoblastic leukemia/lymphoma (precursor T-acute lymphoblastic leukemia ‡ Formerly known as lymphoplasmacytoid lymphoma or immunocytoma II Entities formally grouped under the heading large granular lymphocyte leukemia of T- and NK-cell types * Provisional entities in the REAL classification Mature (peripheral) T neoplasms T-cell chronic lymphocytic leukemia T-cell prolymphocytic leukemia T-cell granular lymphocytic leukemiaII Aggressive NK leukemia Adult T-cell lymphoma/leukemia (HTLV-1+) Extranodal NK/T-cell lymphoma, nasal type# Enteropathy-like T-cell lymphoma** Hepatosplenicγδ T-cell lymphoma* Subcutaneous panniculitis-like T-cell lymphoma* Mycosis fungoides/Sézary syndrome Anaplastic large cell lymphoma, T/null cell, primary cutaneous type Peripheral T-cell lymphoma, not otherwise characterized Angioimmunoblastic T-cell lymphoma Anaplastic large cell lymphoma, T/null cell, primary systemic type WHO/REAL Classification of Lymphoid Neoplasms

  22. Diagnosis * Gejala klinis + pemeriksaan fisik * Laboratorium :Leukositosis, limfositosis > 15000 /mm3 anemia normositer/krom, trombositopenia * Sitogenetik kelainan Khr. 12,13,14 kdg khr 6, 11

  23. Stadium0 : Limfositosis > 15000, SST limfositosis > 30 % 1 : Stad.0 + pembesaran KGB 2 : Stad. 0 + hepatosplenomegali dengan / tanpa pemebesaran KGB 3 : Stad. 0 + anemia (Hb < 11 gr% ) dgn / tanpa stad 1, 2 4 : Stad.0 + trombositopenia ( < 100000 / mm3 )

  24. Penatalaksanaan1. Terapiumum2. Terapikhususdiberikanbila : - anemia, trombositopenia, limfositosisprogresif, sepsis rekuren, anemia hemolitikautoimun, splenomegalimasif, KGB sangatbesar- Klorambusil 0,1 – 0,2 mg / kgBB ( Leukeran 5mg ), leukosit. turun 50 % dosis 50 %, bilaleukosit < 15000 obatdistop- Prednisonatasindikasi : a. infiltrasi SST denganpansitopeni b. Hemolisisatautrombositopeniotoimunklorambusi 0,7 mg / KgBBtiapmingguprednison 0,5 mg / kgBB / hariselama 7 haritiapbulan, bilasudahterkontrol 6 – 8 bulanobatdistop.- Siklofospamid 200 mg / m2tiaphariselama 5 haritiap 3 mingguatasindikasiBilakorambusiltaktertoleransi / takadakemajuan- Fludarabin 25 mg / m2tiaphariselama 5 haritiap 3 mingguselama 6 – 8 bulanatasindikasiciklofospamidgagal. - RadioterapiapabilaSplenomegalimasif ,Penekananbronkus / vena kava- Gama globulin 200 – 400 mg / kgBBtiap 3 minggubilaterjadirekureninfeksi / hipogamaglobulin

  25. TERIMA KASIH

More Related